A Multi-Center, Open Label, Two Part, Dose Escalation Study To Determine The Tolerability Of Interferon-Beta Gene Transfer (BG00001) [interferon-beta gene therapy] In The Treatment Of Recurrent Or Progressive Glioblastoma Multiforme

Trial Profile

A Multi-Center, Open Label, Two Part, Dose Escalation Study To Determine The Tolerability Of Interferon-Beta Gene Transfer (BG00001) [interferon-beta gene therapy] In The Treatment Of Recurrent Or Progressive Glioblastoma Multiforme

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2009

At a glance

  • Drugs Interferon-beta gene therapy (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top